Swedish Orphan Biovitrum GmbH secures contract for Pharmaceutical products - Agreement in accordance with Section 130c Paragraph 1 SGB V on the granting of discounts for patent-protected drugs with the active ingredient Eftrenonacog alfa (Alprolix(r))

Germany, Sept. 29 -- Germany based Swedish Orphan Biovitrum GmbH has secured contract from AOK Baden-Wurttemberg for Pharmaceutical products - Agreement in accordance with Section 130c Paragraph 1 SGB V on the granting of discounts for patent-protected drugs with the active ingredient Eftrenonacog alfa (Alprolix(r)). The value of the contract is not disclosed.

Published by HT Digital Content Services with permission from Pivotal Sources....